Kexing Biopharm has announced a strategic partnership with IQVIA, a global leader in clinical research and healthcare intelligence, to accelerate the international development and commercialization of Kexing’s innovative drugs and biosimilars. The collaboration aims to fast-track Kexing’s entry into Europe and other regulated global markets.
The alliance will leverage IQVIA’s global clinical trial infrastructure, regulatory expertise, and data-driven insights to support Kexing’s expanding pipeline, which focuses on therapeutic areas including antiviral, antitumor, immunosuppressant, and metabolic diseases.
“This partnership represents a major milestone in Kexing’s globalization strategy,” said Yanqing Zhao, CEO of Kexing Biopharm. “IQVIA’s deep clinical data resources and regulatory experience will help optimize our development strategy and accelerate product registration timelines.”
Kexing has already made significant strides in overseas markets. Its in-licensed nab-paclitaxel has gained rapid approvals and market launches in several key jurisdictions. The company continues to invest in R&D and expand its international footprint, positioning itself as a growing force in global biopharma.
Brian Mi, President of IQVIA Asia Pacific, praised Kexing’s progress in innovation and global commercialization: “Our collaboration will unlock new opportunities and support Kexing’s transition into a world-class biopharmaceutical innovator.”
As part of its long-term strategy, Kexing Biopharm is focused on combining innovation and internationalization to bring high-quality Chinese pharmaceutical innovations to patients worldwide. This latest alliance with IQVIA is expected to significantly enhance its global capabilities and accelerate its vision of becoming a leading player in the international healthcare arena.